Co-Diagnostics faces a critical inflection point as legacy pandemic-driven revenue has collapsed to $146,000 in 2026Q1, leaving the firm reliant on an unproven point-of-care hardware platform. The company's persistent inability to achieve profitability, eviden...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 13, 2026 | -$1.46+51.3% vs -$3.00 | $166,131+25.3% vs $132,576 |
Q2 2026 May 14, 2026 | -$4.06-8.3% vs -$3.75 | $145,954+14.9% vs $127,052 |
Q2 2026 Mar 31, 2026 | -$16.35-354.2% vs -$3.60 | $262,489+108.5% vs $125,883 |
Q4 2025 Nov 13, 2025 | -$4.80+15.9% vs -$5.71 | $145,380+15.4% vs $126,000 |
Roundtable discussion, taking place in New York City, will examine the ongoing Ebola outbreak and technologies needed to strengthen future outbreak response. Co-Dx will join officials from the U.S. Department of State's Bureau of Global Health Security and Diplomacy and leaders from across the global health research and development community.
SALT LAKE CITY, Sept. 17, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it will participate in the upcoming joint WHO/Unitaid/UNAIDS Annual Consultation Meeting.
Co-Diagnostics, Inc. (CODX) Shareholder/Analyst Call Transcript
Blood-based testing could open new markets for the Co-Dx® PCR platform, including HIV and hepatitis B and C Co-Diagnostics and ReadyGo target decentralized Ebola detection as the first application of their collaboration Combining GoCollect® sample preparation with Co-Dx PCR technology could bring blood-based molecular testing closer to patients Company to hold in-person press conference and live webcast today at 10:30 a.m. ET SALT LAKE CITY, Sept.
Benchmark CODX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Co-Diagnostics, Inc. (CODX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.10 | $1.23M | -0.03 | -84.1% | -7533.62% | -125.16% | — | |
| $10.34 | $705.09M | -0.62 | -1.89% | -39.2% | -55.3% | — | |
| $21.27 | $604.08M | -10.80 | 13.83% | -26.05% | -7.91% | — | |
| $4.57 | $2.37B | -26.88 | 40.34% | -0.74% | -5.38% | — | |
| $10.55 | $1.73B | 4.15 | 64.69% | -59.87% | — | — | |
| $76.01 | $16.97B | 30.53 | 1.74% | 13.18% | 11.01% | — |
Co-Diagnostics, Inc. (CODX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Co-Diagnostics, Inc. (CODX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 13, 2026·SEC
Jul 31, 2026·SEC
Jul 27, 2026·SEC
Get notified when CODX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Co-Diagnostics, Inc. (CODX) stock FAQ — growth, dividends, profitability & financials explained
Co-Diagnostics, Inc. (CODX) reported $0.7M in revenue for fiscal year 2025.
Co-Diagnostics, Inc. (CODX) saw revenue decline by 84.1% over the past year.
Co-Diagnostics, Inc. (CODX) reported a net loss of $47.1M for fiscal year 2025.
Co-Diagnostics, Inc. (CODX) has a return on equity (ROE) of -125.2%. Negative ROE indicates the company is unprofitable.
Co-Diagnostics, Inc. (CODX) had negative free cash flow of $27.5M in fiscal year 2025, likely due to heavy capital investments.
